Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Movers

On this episode of Stock Movers: - Shares of Moderna (MRNA) surged by a record 101% - the stock’s biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with partner Merck & Co.’s Keytruda helped cut the recurrence of melanoma in a large, late-stage trial. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday. - Shares of Estee Lauder (...

Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning

The companies say the vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

By Carolyn Y. Johnson

Moderna’s cancer shot: exciting for investors, inconclusive for patients

A glimmer of hope for sufferers, a potential revenue platform for a cash-burner, and a whole heap of unknowns

Merck and Moderna say mRNA melanoma vaccine hits goals in late-stage trial

Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.

Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

Merck, Moderna claim encouraging melanoma vaccine trial results

US pharmaceutical firms Merck and Moderna announced on Wednesday encouraging results from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval. The vaccine, called intismeran autogene, showed “statistically significant and clinically meaningful improvements” for skin cancer patients when used with Merck’s Keytruda treatment, the companies said in a statement. Unlike conventional vaccines, so-called therapeutic vaccines like intismeran treat rather...

By Agence France-Presse

Moderna’s stock doubles on promising cancer-vaccine results

The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda.

By Jaimy Lee

Moderna Shares Skyrocket 95% Toward Best Day Ever—On Success Of Cancer Drug Trial

The trial marked the first successful final-stage study for any mRNA-based cancer therapy.

By Ty Roush, Forbes Staff

Moderna stock jumps 120% after cancer vaccine trial win: What investors need to know

Moderna stock surged after its mRNA cancer vaccine showed positive Phase 3 results with Merck’s Keytruda, boosting hopes for a new melanoma treatment.

Moderna surges on trial win for cancer shot; William Blair upgrades

Moderna shares jump 60% on melanoma vaccine trial

Shares in pharma giant Moderna soared about 60% in premarket trading after the company, in a joint statement with Merck, said its mRNA vaccine, combined with Merck's immunothe...

Holy Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial Success

Holy Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial Success Moderna's shares soared as much as 83% in premarket trading in New York after its personalized cancer vaccine, developed in collaboration with Merck & Co., reduced the risk of melanoma returning in a large, late-stage trial. The result marks the first positive Phase 3 trial for a personalized cancer vaccine by any company.  The study met its primary endpoint by showing that the cancer ...

By Tyler Durden